Latest updates
MLN Connects for February 5, 2026
This edition includes information on skilled nursing facility reporting, the January ASC payment update, and more.
MLN Connects for February 5, 2026
This edition includes information on skilled nursing facility reporting, the January ASC payment update, and more.
Use of JW and JZ Modifiers when Billing for Separately Payable Incident-to Supplies
Effective January 1, 2026, the application of the JW and JZ modifiers has changed for certain skin substitutes per the calendar year (CY) 2026 final rule. This article describes the changes.
MLN Connects for January 29, 2026
This edition includes information on PPE & Essential Medicines, DMEPOS, Hospital Price Transparency and more.
National Part A/B MAC Ambulance Supplier Coalition
In response to numerous and continued requests from the ambulance community, the Part A/B Medicare Administrative Contractors (MACs) have put together a National Part A/B MAC Ambulance Supplier…
MLN Connects for January 29, 2026
This edition includes information on PPE & Essential Medicines, DMEPOS, Hospital Price Transparency and more.
National Part A/B MAC Ambulance Supplier Coalition
In response to numerous and continued requests from the ambulance community, the Part A/B Medicare Administrative Contractors (MACs) have put together a National Part A/B MAC Ambulance Supplier…
Avoiding hospice claim rejects
Providers billing Medicare should determine if a patient is enrolled in hospice before billing Medicare Part A. This article has tips on checking patient eligibility and avoiding hospice claim…
NCD 110.24: Chimeric Antigen Receptor (CAR) T-cell therapy
Effective for dates of service on or after August 7, 2019, Medicare will pay claims from approved providers for administration of autologous T-cells expressing at least one CAR for the treatment for…
NCD 110.24: Chimeric Antigen Receptor (CAR) T-cell therapy
Effective for dates of service on or after August 7, 2019, Medicare will pay claims from approved providers for administration of autologous T-cells expressing at least one CAR for the treatment for…